Abstract
Original language | English |
---|---|
Pages (from-to) | 1065-1083 |
Number of pages | 19 |
Journal | Drugs |
Volume | 80 |
Issue number | 11 |
DOIs | |
Publication status | Published - 2020 |
Keywords
- antacid agent
- anti human immunodeficiency virus agent
- antibiotic agent
- anticoagulant agent
- anticonvulsive agent
- antidepressant agent
- antifungal agent
- antilipemic agent
- antineoplastic agent
- antiparkinson agent
- antithrombocytic agent
- cardiovascular agent
- edoxaban
- hepacivirin inhibitor
- hydroxymethylglutaryl coenzyme A reductase inhibitor
- immunomodulating agent
- interleukin 6
- monoclonal antibody
- neuroleptic agent
- nonsteroid antiinflammatory agent
- nootropic agent
- nutraceutical
- nutrition supplement
- omega 3 fatty acid
- clinical practice
- clinician
- drug interaction
- Hepatitis C virus
- herb
- herb drug interaction
- human
- nonhuman
- pharmacodynamics
- pharmacokinetic parameters
- pharmacologist
- Review
Fingerprint
Dive into the research topics of 'Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. / Corsini, A.; Ferri, N.; Proietti, M.; Boriani, G.
In: Drugs, Vol. 80, No. 11, 2020, p. 1065-1083.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
AU - Corsini, A.
AU - Ferri, N.
AU - Proietti, M.
AU - Boriani, G.
N1 - Cited By :2 Export Date: 5 March 2021 CODEN: DRUGA Correspondence Address: Proietti, M.; Department of Clinical Sciences and Community Health, Via della Commenda 19, Italy; email: marco.proietti@unimi.it Chemicals/CAS: edoxaban, 480449-70-5, 480449-71-6, 912273-65-5 References: Boriani, G., Diemberger, I., Martignani, C., Biffi, M., Branzi, A., The epidemiological burden of atrial fibrillation: a challenge for clinicians and health care systems (2006) Eur Heart J, 27, pp. 893-894. , PID: 16543253; Lip, G.Y., Laroche, C., Ioachim, P.M., Rasmussen, L.H., Vitali-Serdoz, L., Petrescu, L., Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry) (2014) Eur Heart J, 35 (47), pp. 3365-3376. , COI: 1:CAS:528:DC%2BC2sXhs1agtL3F, PID: 25176940; Boriani, G., Proietti, M., Laroche, C., Fauchier, L., Marin, F., Nabauer, M., Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry (2018) Europace, 20 (5), pp. 747-757. , PID: 29016832; Boriani, G., Asymptomatic atrial fibrillation: clinical correlates, management and outcomes in the EORP-AF Pilot General Registry (2014) Am J Med., 128, pp. 509-518. , PID: 25534423; Timp, J.F., Braekkan, S.K., Versteeg, H.H., Cannegieter, S.C., Epidemiology of cancer-associated venous thrombosis (2013) Blood, 122 (10), pp. 1712-1723. , COI: 1:CAS:528:DC%2BC3sXhsVGjtLvK, PID: 23908465; Steffel, J., Verhamme, P., Potpara, T.S., Albaladejo, P., Antz, M., Desteghe, L., The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2018) Eur Heart J, 39 (16), pp. 1330-1393. , COI: 1:CAS:528:DC%2BC1MXktVOksL4%3D, PID: 29562325; Lip, G.Y.H., Banerjee, A., Boriani, G., Chiang, C.E., Fargo, R., Freedman, B., Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report (2018) Chest, 154 (5), pp. 1121-1201. , PID: 30144419; Go, A.S., Hylek, E.M., Phillips, K.A., Chang, Y., Henault, L.E., Selby, J.V., Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study (2001) JAMA, 285 (18), pp. 2370-2375. , COI: 1:STN:280:DC%2BD3M3ntleitQ%3D%3D, PID: 11343485; Lloyd-Jones, D.M., Wang, T.J., Leip, E.P., Larson, M.G., Levy, D., Vasan, R.S., Lifetime risk for development of atrial fibrillation: the Framingham Heart Study (2004) Circulation, 110 (9), pp. 1042-1046. , PID: 15313941; Miyasaka, Y., Barnes, M.E., Gersh, B.J., Cha, S.S., Bailey, K.R., Abhayaratna, W.P., Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence (2006) Circulation, 114 (2), pp. 119-125. , PID: 16818816; Go, A.S., Mozaffarian, D., Roger, V.L., Benjamin, E.J., Berry, J.D., Blaha, M.J., Heart disease and stroke statistics–2014 update: a report from the American Heart Association (2014) Circulation, 129 (3), pp. e28-e292. , PID: 24352519; Coppens, M., Eikelboom, J.W., Hart, R.G., Yusuf, S., Lip, G.Y., Dorian, P., The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy (2013) Eur Heart J, 34 (3), pp. 170-176. , COI: 1:CAS:528:DC%2BC3sXht1OjtL4%3D, PID: 23018151; Nutescu, E.A., Shapiro, N.L., Ibrahim, S., West, P., Warfarin and its interactions with foods, herbs and other dietary supplements (2006) Expert Opin Drug Saf, 5 (3), pp. 433-451. , COI: 1:CAS:528:DC%2BD28Xkt12gtr4%3D, PID: 16610971; Teklay, G., Shiferaw, N., Legesse, B., Bekele, M.L., Drug-drug interactions and risk of bleeding among inpatients on warfarin therapy: a prospective observational study (2014) Thromb J, 12, p. 20. , PID: 25249791; https://www.medicinesorguk/emc/product/6905, [Internet] Sde. Lixiana 60mg Film-Coated Tablets. Summary of Product Characteristics (SPC)d(eMC) [Internet]. Last Updated on eMC 31 July 2017, Accessed 4 Jan 2018; (2018), https://www.emaeuropaeu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002629/WC500189045.pdf; Ay, C., Pabinger, I., Cohen, A.T., Cancer-associated venous thromboembolism: burden, mechanisms, and management (2017) Thromb Haemost, 117 (2), pp. 219-230. , PID: 27882374; Firkins, R., Eisfeld, H., Keinki, C., Buentzel, J., Hochhaus, A., Schmidt, T., The use of complementary and alternative medicine by patients in routine care and the risk of interactions (2018) J Cancer Res Clin Oncol, 144 (3), pp. 551-557. , COI: 1:CAS:528:DC%2BC1cXhslChtrw%3D, PID: 29356888; Davis, E.L., Oh, B., Butow, P.N., Mullan, B.A., Clarke, S., Cancer patient disclosure and patient-doctor communication of complementary and alternative medicine use: a systematic review (2012) Oncologist, 17 (11), pp. 1475-1481. , PID: 22933591; Mosher, D.F., Blood coagulation and fibrinolysis: an overview (1990) Clin Cardiol, 13, pp. VI5-VI11. , COI: 1:STN:280:DyaK3c3osVWgtw%3D%3D, PID: 2191814; Eriksson, B.I., Quinlan, D.J., Weitz, J.I., Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development (2009) Clin Pharmacokinet, 48 (1), pp. 1-22. , COI: 1:CAS:528:DC%2BD1MXis12nt7g%3D, PID: 19071881; Furugohri, T., Isobe, K., Honda, Y., Kamisato-Matsumoto, C., Sugiyama, N., Nagahara, T., DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles (2008) J Thromb Haemost, 6 (9), pp. 1542-1549. , COI: 1:CAS:528:DC%2BD1cXhtFyqurzN, PID: 18624979; Matsushima, N., Lee, F., Sato, T., Weiss, D., Mendell, J., Bioavailability and safety of the factor Xa inhibitor edoxaban and the effects of quinidine in healthy subjects (2013) Clin Pharmacol Drug Dev, 2 (4), pp. 358-366. , COI: 1:CAS:528:DC%2BC2cXhs12gtb7N, PID: 27121940; Ogata, K., Mendell-Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers (2010) J Clin Pharmacol, 50 (7), pp. 743-753. , COI: 1:CAS:528:DC%2BC3cXpt1ejtLw%3D, PID: 20081065; Parasrampuria, D.A., Kanamaru, T., Connor, A., Wilding, I., Ogata, K., Shimoto, Y., Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule (2015) J Clin Pharmacol, 55 (11), pp. 1286-1292. , COI: 1:CAS:528:DC%2BC2MXhs1altbnI, PID: 25969414; Hakeam, H.A., Al-Sanea, N., Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs) (2017) J Thromb Thrombolysis, 43 (3), pp. 343-351. , COI: 1:CAS:528:DC%2BC2sXkvFSktQ%3D%3D, PID: 28050755; Mendell, J., Tachibana, M., Shi, M., Kunitada, S., Effects of food on the pharmacokinetics of edoxaban, an oral direct factor Xa inhibitor, in healthy volunteers (2011) J Clin Pharmacol, 51 (5), pp. 687-694. , COI: 1:CAS:528:DC%2BC3MXntVCgsLk%3D, PID: 20534818; Logrippo, S., Ricci, G., Sestili, M., Cespi, M., Ferrara, L., Palmieri, G.F., Oral drug therapy in elderly with dysphagia: between a rock and a hard place! (2017) Clin Interv Aging, 12, pp. 241-251. , COI: 1:CAS:528:DC%2BC1cXhtlertbfP, PID: 28203065; Coluzzi, P.H., Fairbairn, B.S., The management of pain in terminally ill cancer patients with difficulty swallowing (1999) Am J Hosp Palliat Care., 16 (6), pp. 731-737. , COI: 1:STN:280:DC%2BD3MzgvVCgtw%3D%3D, PID: 11094910; Ferreira Silva, R., Novaes, M.R.C.G., Interactions between drugs and drug-nutrient in enteral nutrition: a review based on evidences (2014) Nutr Hosp., 30 (3), pp. 514-518. , PID: 25238825; Duchin, K., Duggal, A., Atiee, G.J., Kidokoro, M., Takatani, T., Shipitofsky, N.L., An Open-label crossover study of the pharmacokinetics of the 60-mg edoxaban tablet crushed and administered either by a nasogastric tube or in apple puree in healthy adults (2018) Clin Pharmacokinet, 57 (2), pp. 221-228. , COI: 1:CAS:528:DC%2BC2sXnvVGjt7s%3D, PID: 28512699; Mikkaichi, T., Yoshigae, Y., Masumoto, H., Imaoka, T., Rozehnal, V., Fischer, T., Edoxaban transport via P-glycoprotein is a key factor for the drug's disposition (2014) Drug Metab Dispos, 42 (4), pp. 520-528. , PID: 24459178; Aller, S.G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding (2009) Science, 323 (5922), pp. 1718-1722. , COI: 1:CAS:528:DC%2BD1MXjs1Kgtro%3D, PID: 19325113; Parasrampuria, D.A., Truitt, K.E., Pharmacokinetics and pharmacodynamics of edoxaban, a non-vitamin K antagonist oral anticoagulant that inhibits clotting factor Xa (2016) Clin Pharmacokinet, 55 (6), pp. 641-655. , COI: 1:CAS:528:DC%2BC2MXhvFGkt7zN, PID: 26620048; Steffel, J., Giugliano, R.P., Braunwald, E., Murphy, S.A., Mercuri, M., Choi, Y., Edoxaban versus warfarin in atrial fibrillation patients at risk of falling: ENGAGE AF-TIMI 48 analysis (2016) J Am Coll Cardiol, 68 (11), pp. 1169-1178. , COI: 1:CAS:528:DC%2BC28XhsVyjs73O, PID: 27609678; Toda Kato, E., Giugliano, R.P., Ruff, C.T., Efficacy and safety of edoxaban for the management of elderly patients with atrial fibrillation: engage AF-TIMI 48 (2014) Circulation, 130, p. A16612; Kato, E.T., Giugliano, R.P., Ruff, C.T., Koretsune, Y., Yamashita, T., Kiss, R.G., Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial (2016) J Am Heart Assoc., 5 (5). , PID: 27207971; Ruff, C.T., Giugliano, R.P., Braunwald, E., Hoffman, E.B., Deenadayalu, N., Ezekowitz, M.D., Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (2014) Lancet, 383 (9921), pp. 955-962. , COI: 1:CAS:528:DC%2BC3sXhvFyqtrjF, PID: 24315724; Bohula, E.A., Giugliano, R.P., Ruff, C.T., Kuder, J.F., Murphy, S.A., Antman, E.M., Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 trial (2016) Circulation, 134 (1), pp. 24-36. , COI: 1:CAS:528:DC%2BC28XhtVyitL3F, PID: 27358434; Krekels, E.H., Niebecker, R., Karlsson, M.O., Miller, R., Shimizu, T., Karlsson, K.E., Population pharmacokinetics of edoxaban in patients with non-valvular atrial fibrillation in the ENGAGE AF-TIMI 48 study, a phase III clinical trial (2016) Clin Pharmacokinet, 55 (9), pp. 1079-1090. , COI: 1:CAS:528:DC%2BC28XjvFGqtrk%3D, PID: 26951208; Grundvold, I., Body weight and risk of atrial fibrillation in 7,169 patients with newly diagnosed type 2 diabetes; an observational study (2015) Cardiovasc Diabetol, 14, p. 5. , PID: 25589001; Adeli, K., Taghibiglou, C., Van Iderstine, S.C., Lewis, G.F., Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance (2001) Trends Cardiovasc Med, 11 (5), pp. 170-176. , COI: 1:CAS:528:DC%2BD3MXntlOqtrs%3D, PID: 11597827; Lindner, S.M., Fordyce, C.B., Hellkamp, A.S., Lokhnygina, Y., Piccini, J.P., Breithardt, G., Treatment consistency across levels of baseline renal function with rivaroxaban or warfarin: a ROCKET AF (rivaroxaban once-daily, oral, direct factor Xa Inhibition Compared With Vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation) analysis (2017) Circulation, 135 (10), pp. 1001-1003. , COI: 1:CAS:528:DC%2BC2sXjs1Kmt7c%3D, PID: 28264892; Bathala, M.S., Masumoto, H., Oguma, T., He, L., Lowrie, C., Mendell, J., Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans (2012) Drug Metab Dispos, 40 (12), pp. 2250-2255. , COI: 1:CAS:528:DC%2BC38XhslyjsrnN, PID: 22936313; Jonsson, S., Simonsson, U.S., Miller, R., Karlsson, M.O., Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study (2015) J Clin Pharmacol, 55 (11), pp. 1268-1279. , PID: 25966665; Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.C., Hacke, W., Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation (2015) Europace, 17 (10), pp. 1467-1507. , PID: 26324838; Gnoth, M.J., Buetehorn, U., Muenster, U., Schwarz, T., Sandmann, S., In vitro and in vivo P-glycoprotein transport characteristics of rivaroxaban (2011) J Pharmacol Exp Ther, 338 (1), pp. 372-380. , COI: 1:CAS:528:DC%2BC3MXosFChs7k%3D, PID: 21515813; Gosselin, R.C., Adcock, D.M., Bates, S.M., Douxfils, J., Favaloro, E.J., Gouin-Thibault, I., International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of direct oral anticoagulants (2018) Thromb Haemost, 118 (3), pp. 437-450. , PID: 29433148; Testa, S., Tripodi, A., Legnani, C., Pengo, V., Abbate, R., Dellanoce, C., Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics (2016) Thromb Res, 137, pp. 178-183. , COI: 1:CAS:528:DC%2BC2MXhvFOmur3N, PID: 26672898; Hirsh Raccah, B., Rottenstreich, A., Zacks, N., Muszkat, M., Matok, I., Perlman, A., Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients (2018) J Thromb Thrombolysis, 46 (4), pp. 521-527. , COI: 1:CAS:528:DC%2BC1cXhs1ylsLzO, PID: 30196343; Stöllberger, C., Drug interactions with new oral anticoagulants in elderly patients (2017) Expert Rev Clin Pharmacol, 10 (11), pp. 1191-1202. , PID: 28825849; Giugliano, R.P., Ruff, C.T., Braunwald, E., Murphy, S.A., Wiviott, S.D., Halperin, J.L., Edoxaban versus warfarin in patients with atrial fibrillation (2013) N Engl J Med, 369 (22), pp. 2093-2104. , COI: 1:CAS:528:DC%2BC3sXhvFWqtrzJ; GaBHaPMaSAaSMaSLavKRaMM, R., Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study–methodological implications for clinical trials (2013) J Thromb Haemost, 11 (7), pp. 1287-1294; Mendell, J., Zahir, H., Matsushima, N., Noveck, R., Lee, F., Chen, S., Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor (2013) Am J Cardiovasc Drugs, 13 (5), pp. 331-342. , COI: 1:CAS:528:DC%2BC3sXhsl2nur7L, PID: 23784266; Holtzman, C.W., Wiggins, B.S., Spinler, S.A., Role of P-glycoprotein in statin drug interactions (2006) Pharmacotherapy, 26 (11), pp. 1601-1607. , COI: 1:CAS:528:DC%2BD28Xht1ymsrrN, PID: 17064205; Steffel, J., Giugliano, R.P., Braunwald, E., Murphy, S.A., Atar, D., Heidbuchel, H., Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial (2015) Eur Heart J., 36 (33), pp. 2239-2245. , COI: 1:CAS:528:DC%2BC28XitFertrnL, PID: 25971288; (2015), SAVAYSA FDA SmPC; Salazar, D.E., Mendell, J., Kastrissios, H., Green, M., Carrothers, T.J., Song, S., Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation (2012) Thromb Haemost, 107 (5), pp. 925-936. , COI: 1:CAS:528:DC%2BC38XosFaqtb4%3D, PID: 22398655; Lixiana 60Mg Film-Coated Tablets. Summary of Product Characteristics (Spc)D(Emc), , https://www.medicinesorguk/emc/product/6905/smpc, [Internet]. Last updated on eMC: 10 Aug 2018, Accessed 22 Oct 2018; Aisenberg, J., Chatterjee-Murphy, P., Friedman Flack, K., Weitz, J.I., Ruff, C.T., Nordio, F., Gastrointestinal bleeding with edoxaban versus warfarin: results from the ENGAGE AF-TIMI 48 trial (effective anticoagulation with factor Xa next generation in atrial fibrillation-thrombolysis in myocardial infarction) (2018) Circ Cardiovasc Qual Outcomes, 11 (5). , PID: 29748353; Hansen, M.L., Sorensen, R., Clausen, M.T., Fog-Petersen, M.L., Raunso, J., Gadsboll, N., Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation (2010) Arch Intern Med, 170 (16), pp. 1433-1441. , COI: 1:CAS:528:DC%2BC3cXht1aqu7%2FI, PID: 20837828; Mendell, J., Lee, F., Chen, S., Worland, V., Shi, M., Samama, M.M., The effects of the antiplatelet agents, aspirin and naproxen, on pharmacokinetics and pharmacodynamics of the anticoagulant edoxaban, a direct factor Xa inhibitor (2013) J Cardiovasc Pharmacol, 62 (2), pp. 212-221. , COI: 1:CAS:528:DC%2BC3sXht1amt7vI, PID: 23615159; Xu, H., Ruff, C.T., Giugliano, R.P., Murphy, S.A., Nordio, F., Patel, I., Concomitant use of single antiplatelet therapy with edoxaban or warfarin in patients with atrial fibrillation: analysis from the ENGAGE AF-TIMI48 trial (2016) J Am Heart Assoc., 5 (2). , PID: 26908401; Wessler, J.D., Grip, L.T., Mendell, J., Giugliano, R.P., The P-glycoprotein transport system and cardiovascular drugs (2013) J Am Coll Cardiol, 61 (25), pp. 2495-2502. , COI: 1:CAS:528:DC%2BC3sXpvVylsr8%3D; Oh, J., Shin, D., Lim, K.S., Lee, S., Jung, K.H., Chu, K., Aspirin decreases systemic exposure to clopidogrel through modulation of P-glycoprotein but does not alter its antithrombotic activity (2014) Clin Pharmacol Ther, 95 (6), pp. 608-616. , COI: 1:CAS:528:DC%2BC2cXlvVSnsbo%3D, PID: 24566733; Teng, R., Butler, K., A pharmacokinetic interaction study of ticagrelor and digoxin in healthy volunteers (2013) Eur J Clin Pharmacol, 69 (10), pp. 1801-1808. , COI: 1:CAS:528:DC%2BC3sXhsVOmsrbF, PID: 23748750; Teng, R., Mitchell, P., Butler, K., Effect of rifampicin on the pharmacokinetics and pharmacodynamics of ticagrelor in healthy subjects (2013) Eur J Clin Pharmacol, 69 (4), pp. 877-883. , PID: 23093043; Mega, J.L., Close, S.L., Wiviott, S.D., Shen, L., Walker, J.R., Simon, T., Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis (2010) Lancet, 376 (9749), pp. 1312-1319. , COI: 1:CAS:528:DC%2BC3cXht12ks7jF, PID: 20801494; Gelosa, P., Castiglioni, L., Tenconi, M., Baldessin, L., Racagni, G., Corsini, A., Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs) (2018) Pharmacol Res, 135, pp. 60-79. , COI: 1:CAS:528:DC%2BC1cXhsVWhsLbP, PID: 30040996; Wiggins, B.S., Saseen, J.J., Page, R.L., 2nd, Reed, B.N., Sneed, K., Kostis, J.B., Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart association (2016) Circulation, 134 (21), pp. e468-e495. , PID: 27754879; Antoniou, T., Macdonald, E.M., Yao, Z., Hollands, S., Gomes, T., Tadrous, M., Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation (2017) CMAJ Can Med Assoc J, 189 (1), pp. E4-E10; Boyd, R.A., Stern, R.H., Stewart, B.H., Wu, X., Reyner, E.L., Zegarac, E.A., Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion (2000) J Clin Pharmacol, 40 (1), pp. 91-98. , COI: 1:CAS:528:DC%2BD3cXivF2ksbc%3D, PID: 10631627; Schelleman, H., Bilker, W.B., Brensinger, C.M., Wan, F., Yang, Y.X., Hennessy, S., Fibrate/Statin initiation in warfarin users and gastrointestinal bleeding risk (2010) Am J Med, 123 (2), pp. 151-157. , COI: 1:CAS:528:DC%2BC3cXpslelug%3D%3D, PID: 20103024; Corsini, A., Bellosta, S., Davidson, M.H., Pharmacokinetic interactions between statins and fibrates (2005) Am J Cardiol., 96 (9A), pp. 44K-K49. , COI: 1:CAS:528:DC%2BD2MXhtlGgs7vK, PID: 16291014, (discussion 34K–5K; Prueksaritanont, T., Tang, C., Qiu, Y., Mu, L., Subramanian, R., Lin, J.H., Effects of fibrates on metabolism of statins in human hepatocytes (2002) Drug Metab Dispos, 30 (11), pp. 1280-1287. , COI: 1:CAS:528:DC%2BD38XotFyku7Y%3D, PID: 12386136; Ehrhardt, M., Lindenmaier, H., Burhenne, J., Haefeli, W.E., Weiss, J., Influence of lipid lowering fibrates on P-glycoprotein activity in vitro (2004) Biochem Pharmacol, 67 (2), pp. 285-292. , COI: 1:CAS:528:DC%2BD3sXpvF2qsLs%3D, PID: 14698041; Yamazaki, M., Li, B., Louie, S.W., Pudvah, N.T., Stocco, R., Wong, W., Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport (2005) Xenobiotica, 35 (7), pp. 737-753. , COI: 1:CAS:528:DC%2BD2MXht1Sns73F, PID: 16316932; Henry, C.A., Lyon, R.A., Ling, H., Clinical efficacy and safety of evolocumab for low-density lipoprotein cholesterol reduction (2016) Vasc Health Risk Manag, 12, pp. 163-169. , COI: 1:CAS:528:DC%2BC1cXmsVOqsLc%3D, PID: 27143910; Gouin-Thibault, I., Delavenne, X., Blanchard, A., Siguret, V., Salem, J.E., Narjoz, C., Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycin (2017) J Thromb Haemost, 15 (2), pp. 273-283. , COI: 1:CAS:528:DC%2BC2sXisV2murk%3D, PID: 27893182; Hughes, J., Crowe, A., Inhibition of P-glycoprotein-mediated efflux of digoxin and its metabolites by macrolide antibiotics (2010) J Pharmacol Sci, 113 (4), pp. 315-324. , COI: 1:CAS:528:DC%2BC3cXhtFegtLrK, PID: 20724802; Parasrampuria, D.A., Mendell, J., Shi, M., Matsushima, N., Zahir, H., Truitt, K., Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine (2016) Br J Clin Pharmacol, 82 (6), pp. 1591-1600. , COI: 1:CAS:528:DC%2BC28Xhsl2hur7J, PID: 27530188; Greiner, B., Eichelbaum, M., Fritz, P., Kreichgauer, H.P., von Richter, O., Zundler, J., The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin (1999) J Clin Investig, 104 (2), pp. 147-153. , COI: 1:CAS:528:DyaK1MXkslSmsb8%3D, PID: 10411543; Schuetz, E.G., Schinkel, A.H., Relling, M.V., Schuetz, J.D., P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans (1996) Proc Natl Acad Sci USA, 93 (9), pp. 4001-4005. , COI: 1:CAS:528:DyaK28XivVKrtbg%3D, PID: 8633005; Mendell, J., Chen, S., He, L., Desai, M., Parasramupria, D.A., The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults (2015) Clin Drug Investig, 35 (7), pp. 447-453. , COI: 1:CAS:528:DC%2BC2MXhtVOhsrbJ, PID: 26068927; Roedler, R., Neuhauser, M.M., Penzak, S.R., Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered? (2007) Ann Pharmacother, 41 (4), pp. 653-658. , COI: 1:CAS:528:DC%2BD2sXltlOnsrc%3D, PID: 17374625; Michalets, E.L., Williams, C.R., Drug interactions with cisapride: clinical implications (2000) Clin Pharmacokinet, 39 (1), pp. 49-75. , COI: 1:CAS:528:DC%2BD3cXlvVSjurc%3D, PID: 10926350; Kim, K.A., Park, J.Y., Effect of metronidazole on the pharmacokinetics of fexofenadine, a P-glycoprotein substrate, in healthy male volunteers (2010) Eur J Clin Pharmacol, 66 (7), pp. 721-725. , COI: 1:CAS:528:DC%2BC3cXntlKqtbk%3D, PID: 20306185; Heit, J.A., Silverstein, M.D., Mohr, D.N., Petterson, T.M., O'Fallon, W.M., Melton, L.J., 3rd, Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study (2000) Arch Intern Med, 160 (6), pp. 809-815. , COI: 1:STN:280:DC%2BD3c7pvFGnsw%3D%3D, PID: 10737280; Raskob, G.E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Edoxaban for the treatment of cancer-associated venous thromboembolism (2018) N Engl J Med, 378 (7), pp. 615-624. , COI: 1:CAS:528:DC%2BC1cXktFClsrs%3D, PID: 29231094; Wiczer, T.E., Levine, L.B., Brumbaugh, J., Coggins, J., Zhao, Q., Ruppert, A.S., Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib (2017) Blood Adv, 1 (20), pp. 1739-1748. , COI: 1:CAS:528:DC%2BC1cXls1Omsbs%3D, PID: 29296820; Thorp, B.C., Badoux, X., Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management (2018) Leukemia Lymphoma, 59 (2), pp. 311-320. , COI: 1:CAS:528:DC%2BC2sXhtVChs7nL, PID: 28629235; Boriani, G., Corradini, P., Cuneo, A., Falanga, A., Foa, R., Gaidano, G., Practical management of ibrutinib in the real life: focus on atrial fibrillation and bleeding (2018) Hematol Oncol., 36, pp. 624-632. , COI: 1:CAS:528:DC%2BC1cXhvFGqur3K, PID: 29512173; Gilad, R., Management of seizures following a stroke: what are the options? (2012) Drugs Aging, 29 (7), pp. 533-538. , COI: 1:CAS:528:DC%2BC38XhvVCit7jE, PID: 22540349; Stollberger, C., Finsterer, J., Interactions between non-vitamin K oral anticoagulants and antiepileptic drugs (2016) Epilepsy Res, 126, pp. 98-101. , PID: 27450623; Giessmann, T., May, K., Modess, C., Wegner, D., Hecker, U., Zschiesche, M., Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans (2004) Clin Pharmacol Ther, 76 (3), pp. 192-200. , COI: 1:CAS:528:DC%2BD2cXnslKks74%3D, PID: 15371980; Moerman, L., Wyffels, L., Slaets, D., Raedt, R., Boon, P., De Vos, F., Antiepileptic drugs modulate P-glycoproteins in the brain: a mice study with (11)C-desmethylloperamide (2011) Epilepsy Res, 94 (1-2), pp. 18-25. , COI: 1:CAS:528:DC%2BC3MXjtFSrurw%3D, PID: 21277169; Jing, X., Liu, X., Wen, T., Xie, S., Yao, D., Liu, X., Combined effects of epileptic seizure and phenobarbital induced overexpression of P-glycoprotein in brain of chemically kindled rats (2010) Br J Pharmacol, 159 (7), pp. 1511-1522. , COI: 1:CAS:528:DC%2BC3cXks1OjtLs%3D, PID: 20233212; Alvariza, S., Fagiolino, P., Vazquez, M., Feria-Romero, I., Orozco-Suarez, S., Chronic administration of phenytoin induces efflux transporter overexpression in rats (2014) Pharmacol Rep, 66 (6), pp. 946-951. , COI: 1:CAS:528:DC%2BC2MXmt1Shsbg%3D, PID: 25443719; Eyal, S., Lamb, J.G., Smith-Yockman, M., Yagen, B., Fibach, E., Altschuler, Y., The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver (2006) Br J Pharmacol, 149 (3), pp. 250-260. , COI: 1:CAS:528:DC%2BD28XhtVSgurrM, PID: 16894351; Tang, R., Faussat, A.M., Majdak, P., Perrot, J.Y., Chaoui, D., Legrand, O., Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1 (2004) Leukemia, 18 (7), pp. 1246-1251. , COI: 1:CAS:528:DC%2BD2cXkvF2ku7o%3D, PID: 15116123; Wang-Tilz, Y., Tilz, C., Wang, B., Tilz, G.P., Stefan, H., Influence of lamotrigine and topiramate on MDR1 expression in difficult-to-treat temporal lobe epilepsy (2006) Epilepsia, 47 (2), pp. 233-239. , COI: 1:CAS:528:DC%2BD28Xis1yitLk%3D, PID: 16499746; Lewer, D., O'Reilly, C., Mojtabai, R., Evans-Lacko, S., Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors (2015) Br J Psychiatry, 207 (3), pp. 221-226. , PID: 26159603; Maurer-Spurej, E., Pittendreigh, C., Solomons, K., The influence of selective serotonin reuptake inhibitors on human platelet serotonin (2004) Thromb Haemost, 91 (1), pp. 119-128. , COI: 1:CAS:528:DC%2BD2cXosVWhsQ%3D%3D, PID: 14691577; Schalekamp, T., Klungel, O.H., Souverein, P.C., de Boer, A., Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins (2008) Arch Intern Med, 168 (2), pp. 180-185. , PID: 18227365; (2015) Internet] Sde. Pradaxa 150 Mg Hard Capsules., , https://www.medicinesorguk/emc/medicine/24839, Summary of Product Characteristics (SPC)d(eMC) [Internet]. Last Updated on eMC 30-Jan-2015. Last Updated on eMC 30-Jan-2015; Date of first authorisation: 30 September 2008, , https://www.medicines.org.uk/emc/product/2793/smpc, . Date of latest renewal: 22 May 2018; Weiss, J., Dormann, S.M., Martin-Facklam, M., Kerpen, C.J., Ketabi-Kiyanvash, N., Haefeli, W.E., Inhibition of P-glycoprotein by newer antidepressants (2003) J Pharmacol Exp Ther, 305 (1), pp. 197-204. , COI: 1:CAS:528:DC%2BD3sXis1anurs%3D, PID: 12649369; Kapoor, A., Iqbal, M., Petropoulos, S., Ho, H.L., Gibb, W., Matthews, S.G., Effects of sertraline and fluoxetine on p-glycoprotein at barrier sites: in vivo and in vitro approaches (2013) PLoS ONE, 8 (2). , COI: 1:CAS:528:DC%2BC3sXjvFKisLc%3D, PID: 23468867; Sansone, R.A., Sansone, L.A., Warfarin and antidepressants: happiness without hemorrhaging (2009) Psychiatry, 6 (7), pp. 24-29. , PID: 19724766; Spina, E., de Leon, J., Metabolic drug interactions with newer antipsychotics: a comparative review (2007) Basic Clin Pharmacol Toxicol, 100 (1), pp. 4-22. , COI: 1:CAS:528:DC%2BD2sXivVOrsr8%3D, PID: 17214606; Wang, J.S., Zhu, H.J., Markowitz, J.S., Donovan, J.L., DeVane, C.L., Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein (2006) Psychopharmacology, 187 (4), pp. 415-423. , COI: 1:CAS:528:DC%2BD28XnvVynu7o%3D, PID: 16810505; Moons, T., de Roo, M., Claes, S., Dom, G., Relationship between P-glycoprotein and second-generation antipsychotics (2011) Pharmacogenomics, 12 (8), pp. 1193-1211. , COI: 1:CAS:528:DC%2BC3MXhtVeitL%2FP, PID: 21843066; Wyss-Coray, T., Ageing, neurodegeneration and brain rejuvenation (2016) Nature, 539 (7628), pp. 180-186. , COI: 1:CAS:528:DC%2BC28XhvVaqs7vI, PID: 27830812; Niccoli, T., Partridge, L., Ageing as a risk factor for disease (2012) Curr Biol, 22 (17), pp. R741-R752. , COI: 1:CAS:528:DC%2BC38XhtlCjtLbK, PID: 22975005; Tysnes, O.B., Storstein, A., Epidemiology of Parkinson's disease (2017) J Neural Transm, 124 (8), pp. 901-905; Mayeux, R., Stern, Y., Epidemiology of Alzheimer disease (2012) Cold Spring Harbor Perspect Med., 2 (8), p. a006239; Mittur, A., Gupta, S., Modi, N.B., Pharmacokinetics of Rytary((R)), an extended-release capsule formulation of carbidopa-levodopa (2017) Clin Pharmacokinet, 56 (9), pp. 999-1014. , COI: 1:CAS:528:DC%2BC2sXjsFGitrg%3D, PID: 28236251; Vautier, S., Milane, A., Fernandez, C., Buyse, M., Chacun, H., Farinotti, R., Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood-brain barrier in a rat brain endothelial cell model (2008) Neurosci Lett, 442 (1), pp. 19-23. , COI: 1:CAS:528:DC%2BD1cXptVWqtLY%3D, PID: 18598736; Wynalda, M.A., Wienkers, L.C., Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen (1997) Drug Metab Dispos, 25 (10), pp. 1211-1214. , COI: 1:CAS:528:DyaK2sXmvVWnsb0%3D, PID: 9321526; Muller, T., ABCB1: is there a role in the drug treatment of Parkinson's disease? (2018) Expert Opin Drug Metab Toxicol, 14 (2), pp. 127-129. , PID: 29224383; Pingili, R., Vemulapalli, S., Mullapudi, S.S., Nuthakki, S., Pendyala, S., Kilaru, N., Pharmacokinetic interaction study between flavanones (hesperetin, naringenin) and rasagiline mesylate in wistar rats (2016) Drug Dev Ind Pharm, 42 (7), pp. 1110-1117. , COI: 1:CAS:528:DC%2BC2MXhvFeqtr7E, PID: 26530401; Muller, T., Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease (2017) Expert Opin Drug Metab Toxicol, 13 (6), pp. 693-699. , PID: 28537214; Csoti, I., Storch, A., Müller, W., Jost, W.H., Drug interactions with selegiline versus rasagiline (2012) Basal Ganglia, 2, pp. S27-S31; Bicker, J., Fortuna, A., Alves, G., Soares-da-Silva, P., Falcao, A., Elucidation of the Impact of P-glycoprotein and breast cancer resistance protein on the brain distribution of catechol-O-methyltransferase inhibitors (2017) Drug Metab Dispos, 45 (12), pp. 1282-1291. , COI: 1:CAS:528:DC%2BC1cXpsVansLY%3D, PID: 28916530; Dingemanse, J., Meyerhoff, C., Schadrack, J., Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin (2002) Br J Clin Pharmacol, 53 (5), pp. 485-491. , COI: 1:CAS:528:DC%2BD38Xks1Onu7Y%3D, PID: 11994054; Jeong, H.J., Lee, H.S., Kim, K.S., Kim, Y.K., Yoon, D., Park, S.W., Sterol-dependent regulation of proprotein convertase subtilisin/kexin type 9 expression by sterol-regulatory element binding protein-2 (2008) J Lipid Res, 49 (2), pp. 399-409. , COI: 1:CAS:528:DC%2BD1cXhsVaitbY%3D, PID: 17921436; Suzuki, T., Fukami, T., Tomono, K., Possible involvement of cationic-drug sensitive transport systems in the blood-to-brain influx and brain-to-blood efflux of amantadine across the blood-brain barrier (2015) Biopharm Drug Dispos, 36 (2), pp. 126-137. , COI: 1:CAS:528:DC%2BC2cXitFahsL%2FJ, PID: 25410756; Mceneny-King, A., Eginton, A.N., Rao, P.P., Investigating the binding interactions of the anti-Alzheimer's drug donepezil with CYP3A4 and P-glycoprotein (2015) Bioorg Med Chem Lett., 25 (2), pp. 297-301. , COI: 1:CAS:528:DC%2BC2cXitValtbvL, PID: 25499431; Huang, F., Fu, Y., A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients (2010) Curr Clin Pharmacol, 5 (2), pp. 115-124. , COI: 1:CAS:528:DC%2BC3cXntFGhsLc%3D, PID: 20156150; Kraus, W., The national physical activity plan: a call to action from the American heart association: a science advisory from the American heart association (2015) Circulation, 131 (21), pp. 1932-1940. , PID: 25918126; Polinsky, R.J., Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease (1998) Clin Ther., 20 (4), pp. 634-647. , COI: 1:CAS:528:DyaK1cXmtVWmtrY%3D, PID: 9737824; Mohamed, L.A., Keller, J.N., Kaddoumi, A., Role of P-glycoprotein in mediating rivastigmine effect on amyloid-beta brain load and related pathology in Alzheimer's disease mouse model (2016) Biochem Biophys Acta, 1862 (4), pp. 778-787. , COI: 1:CAS:528:DC%2BC28XhtVeju7g%3D, PID: 26780497; West, T.A., Perram, J., Holloway, C.J., Use of direct oral anticoagulants for treatment of atrial fibrillation in patients with HIV: a review (2017) Curr Opin HIV AIDS, 12 (6), pp. 554-560. , COI: 1:CAS:528:DC%2BC2sXhs1SlurrE, PID: 28799998; Caplan, M.R., Daar, E.S., Corado, K.C., Next generation fixed dose combination pharmacotherapies for treating HIV (2018) Expert Opin Pharmacother, 19 (6), pp. 589-596. , COI: 1:CAS:528:DC%2BC1cXlt1SqsLg%3D, PID: 29557204; Clumeck, N., Pozniak, A., Raffi, F., European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults (2008) HIV Med, 9 (2), pp. 65-71. , COI: 1:STN:280:DC%2BD1c3gsFSnsw%3D%3D, PID: 18257769; Tseng, A., Foisy, M., Important drug-drug interactions in HIV-infected persons on antiretroviral therapy: an update on new interactions between HIV and Non-HIV drugs (2012) Curr Infect Dis Rep, 14 (1), pp. 67-82. , PID: 22125049; Mathias, A.A., German, P., Murray, B.P., Wei, L., Jain, A., West, S., Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity (2010) Clin Pharmacol Ther, 87 (3), pp. 322-329. , COI: 1:CAS:528:DC%2BC3cXitVSqtbw%3D, PID: 20043009; Kumar, P., Gordon, L.A., Brooks, K.M., George, J.M., Kellogg, A., McManus, M., Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran (2017) Antimicrob Agents Chemother., 61 (11), pp. e01201-17. , PID: 28848011; Koff, R.S., Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection (2014) Aliment Pharmacol Ther, 39 (5), pp. 478-487. , COI: 1:CAS:528:DC%2BC2cXitFKltLg%3D, PID: 24387618; Garimella, T., You, X., Wang, R., Huang, S.P., Kandoussi, H., Bifano, M., A review of daclatasvir drug-drug interactions (2016) Adv Ther, 33 (11), pp. 1867-1884. , COI: 1:CAS:528:DC%2BC28Xhs1Sktb%2FJ, PID: 27664109; Bertz, R., Bristol-Myers Squibb HCV Full Development Portfolio Overview., , In: Plenary presentation presented at the 14th International Workshop on Clinical Pharmacology, April 22–24, 2014, Amsterdam, The Netherlands; Hodin, S., Basset, T., Jacqueroux, E., Delezay, O., Clotagatide, A., Perek, N., In vitro comparison of the role of P-glycoprotein and breast cancer resistance protein on direct oral anticoagulants disposition (2018) Eur J Drug Metab Pharmacokinet, 43 (2), pp. 183-191. , COI: 1:CAS:528:DC%2BC2sXhsVKks73F, PID: 28895074; Garrison, K.L., German, P., Mogalian, E., Mathias, A., The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection (2018) Drug Metab Dispos, 46, pp. 1212-1225. , COI: 1:CAS:528:DC%2BC1cXhvFGgt73P, PID: 29695614
PY - 2020
Y1 - 2020
N2 - Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now spreading in current clinical practice, being indicated for both thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, the contemporary administration of several drugs can cause relevant drug-drug interactions (DDIs), which can affect drugs’ pharmacokinetics and pharmacodynamics. Usually, all the NOACs are considered to have significantly fewer DDIs than vitamin K antagonists; notwithstanding, this is actually not true, all of them are affected by DDIs with drugs that can influence the activity (induction or inhibition) of P-glycoprotein (P-gp) and cytochrome P450 3A4, both responsible for the disposition and metabolism of NOACs to a different extent. In this review/expert opinion, we focused on an extensive report of edoxaban DDIs. All the relevant drugs categories have been examined to report on significant DDIs, discussing the impact on edoxaban pharmacokinetics and pharmacodynamics, and the evidence for dose adjustment. Our analysis found that, despite a restrained number of interactions, some strong inhibitors/inducers of P-gp and drug-metabolising enzymes can affect edoxaban concentration, just as it happens with other NOACs, implying the need for a dose adjustment. However, our analysis of edoxaban DDIs suggests that given the small propensity for interactions of this agent, its use represents an acceptable clinical decision. Still, DDIs can be significant in certain clinical situations and a careful evaluation is always needed when prescribing NOACs. © 2020, Springer Nature Switzerland AG.
AB - Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now spreading in current clinical practice, being indicated for both thromboprophylaxis in patients with non-valvular atrial fibrillation (NVAF) and for the treatment and prevention of venous thromboembolism (VTE). In patients with multiple conditions, the contemporary administration of several drugs can cause relevant drug-drug interactions (DDIs), which can affect drugs’ pharmacokinetics and pharmacodynamics. Usually, all the NOACs are considered to have significantly fewer DDIs than vitamin K antagonists; notwithstanding, this is actually not true, all of them are affected by DDIs with drugs that can influence the activity (induction or inhibition) of P-glycoprotein (P-gp) and cytochrome P450 3A4, both responsible for the disposition and metabolism of NOACs to a different extent. In this review/expert opinion, we focused on an extensive report of edoxaban DDIs. All the relevant drugs categories have been examined to report on significant DDIs, discussing the impact on edoxaban pharmacokinetics and pharmacodynamics, and the evidence for dose adjustment. Our analysis found that, despite a restrained number of interactions, some strong inhibitors/inducers of P-gp and drug-metabolising enzymes can affect edoxaban concentration, just as it happens with other NOACs, implying the need for a dose adjustment. However, our analysis of edoxaban DDIs suggests that given the small propensity for interactions of this agent, its use represents an acceptable clinical decision. Still, DDIs can be significant in certain clinical situations and a careful evaluation is always needed when prescribing NOACs. © 2020, Springer Nature Switzerland AG.
KW - antacid agent
KW - anti human immunodeficiency virus agent
KW - antibiotic agent
KW - anticoagulant agent
KW - anticonvulsive agent
KW - antidepressant agent
KW - antifungal agent
KW - antilipemic agent
KW - antineoplastic agent
KW - antiparkinson agent
KW - antithrombocytic agent
KW - cardiovascular agent
KW - edoxaban
KW - hepacivirin inhibitor
KW - hydroxymethylglutaryl coenzyme A reductase inhibitor
KW - immunomodulating agent
KW - interleukin 6
KW - monoclonal antibody
KW - neuroleptic agent
KW - nonsteroid antiinflammatory agent
KW - nootropic agent
KW - nutraceutical
KW - nutrition supplement
KW - omega 3 fatty acid
KW - clinical practice
KW - clinician
KW - drug interaction
KW - Hepatitis C virus
KW - herb
KW - herb drug interaction
KW - human
KW - nonhuman
KW - pharmacodynamics
KW - pharmacokinetic parameters
KW - pharmacologist
KW - Review
U2 - 10.1007/s40265-020-01328-6
DO - 10.1007/s40265-020-01328-6
M3 - Article
VL - 80
SP - 1065
EP - 1083
JO - Drugs
JF - Drugs
SN - 0012-6667
IS - 11
ER -